Thiopyrano[2,3-d]thiazole structures as promising scaffold with anticancer potential

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Molecular Pharmacology

Background:

• Novel heterocyclic compounds are crucial for developing targeted cancer therapies.
• Chromenothiopyrano[2,3-d]thiazole scaffold represents a promising area for drug discovery.
• Selective cytotoxicity against cancer cells with minimal impact on normal cells is a key therapeutic goal.

Purpose of the Study:

• To synthesize and evaluate the cytotoxic potential of novel chromenothiopyrano[2,3-d]thiazole derivatives.
• To investigate the mechanism of action of the most potent derivative against cancer cell lines.
• To assess the selectivity of the compound towards tumor versus normal cells.

Main Methods:

• Synthesis of seven chromeno[4',3':4,5]thiopyrano[2,3-d]thiazole derivatives.
• In vitro cytotoxicity screening against human leukemia (Jurkat, K562, HL-60), breast adenocarcinoma (MCF-7, MDA-MB-231), glioblastoma (U251), and normal cell lines (HaCaT, HEK293, Balb/c 3T3, J774.2, Mv1Lu, human lymphocytes).
• Apoptosis induction analysis, DNA damage assessment, reactive oxygen species (ROS) measurement, and mechanistic studies involving mitochondrial pathways and PARP-1 inhibition.

Main Results:

• Derivative 3 exhibited significant cytotoxicity against multiple human cancer cell lines, including Jurkat, K562, U251, HL-60, MCF-7, and MDA-MB-231.
• Compound 3 demonstrated low toxicity towards various normal and pseudo-normal cell lines (IC50 > 100 μM).
• Derivative 3 induced apoptosis in Jurkat and U251 cells via a mitochondria-dependent pathway, inhibiting PARP-1 and causing characteristic morphological changes.
• The compound induced DNA damage and accumulated ROS in cancer cells, with significantly less effect on normal lymphocytes.
• Mechanisms of action were independent of DNA binding/intercalation, highlighting a ROS-mediated mitochondrial pathway.

Conclusions:

• Compound 3 is a potent and selective cytotoxic agent against leukemia and glioblastoma.
• The mechanism involves ROS generation, mitochondrial dysfunction, and apoptosis induction.
• This derivative holds promise as a lead compound for developing novel anti-cancer therapeutics.